ProtoKinetix, Incorporated

Equities

PKTX

US7437221002

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 14:45:58 28/06/2024 BST			5-day change	1st Jan Change
0.01 ^USD	0.00%		-6.54%	-47.37%

05-15	ProtoKinetix, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-29	ProtoKinetix, Incorporated announced a financing transaction	CI

ProtoKinetix, Incorporated announced that it has received $0.05 million in funding

January 11, 2019

On January 12, 2019, ProtoKinetix, Incorporated (OTCPK:PKTX) closed the transaction. The company issued 1,000,000 common shares at $0.05 per share for gross proceeds of $50,000 from from an accredited investor.

Latest news about ProtoKinetix, Incorporated

ProtoKinetix, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
ProtoKinetix, Incorporated announced a financing transaction	03-28	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
ProtoKinetix, Incorporated announced that it expects to receive $0.11 million in funding	12-25	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	18/10/23	CI
ProtoKinetix, Incorporated announced that it has received $0.03 million in funding	28/08/23	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/07/23	CI
ProtoKinetix, Incorporated announced that it has received $0.324 million in funding	24/05/23	CI
ProtoKinetix, Incorporated announced that it has received $0.324 million in funding	24/05/23	CI
ProtoKinetix, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2023	02/05/23	CI
ProtoKinetix, Incorporated Auditor Raises 'Going Concern' Doubt	16/03/23	CI
ProtoKinetix, Incorporated announced that it has received $0.04 million in funding	22/01/23	CI
ProtoKinetix, Incorporated announced a financing transaction	29/12/22	CI
ProtoKinetix, Incorporated announced that it expects to receive $0.037 million in funding	29/12/22	CI
ProtoKinetix, Incorporated announced that it expects to receive $0.063 million in funding	08/12/22	CI
ProtoKinetix, Incorporated announced a financing transaction	07/12/22	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	31/10/22	CI
ProtoKinetix, Incorporated announced that it has received funding	13/10/22	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	29/07/22	CI
ProtoKinetix, Incorporated Completes Phase 1 Clinical Trials for the Treatment of Type 1 Diabetes in Islet Cell Transplants	20/07/22	CI
ProtoKinetix, Incorporated announced a financing transaction	10/07/22	CI
ProtoKinetix, Incorporated announced that it expects to receive $0.2 million in funding	10/07/22	CI
ProtoKinetix, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2022	10/05/22	CI
ProtoKinetix, Incorporated announced that it has received $0.05 million in funding	17/03/22	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2021	10/03/22	CI

Chart ProtoKinetix, Incorporated

Duration

Period

More charts

Company Profile

ProtoKinetix, Incorporated is a research and development stage biotechnology company. The Company is focused on scientific medical research of Anti-Freeze Glycoproteins (AFGPs) or anti-aging glycoproteins. The Companyâs anti-aging glycopeptide is for ophthalmology, dermatology, transplant support and biomanufacturing. The commercial applications for AAGPs include various health care solutions. In a clinical setting, AAGP is showing its ability to protect cells from inflammation, repair and replace damaged cells and improve cell survivability over time. The Company has not developed a commercially viable product and has not generated any revenue.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PROTOKINETIX, INCORPORATED	-47.37%	3.53M
LONZA GROUP AG	+38.65%	39.1B
IQVIA HOLDINGS INC.	-7.47%	38.76B
ALNYLAM PHARMACEUTICALS, INC.	+27.43%	31.24B
ICON PUBLIC LIMITED COMPANY	+13.49%	25.9B
CELLTRION, INC.	-13.50%	25.8B
UNITED THERAPEUTICS CORPORATION	+45.85%	14.06B
MEDPACE HOLDINGS, INC.	+40.20%	13.12B
BIO-TECHNE CORPORATION	-6.64%	11.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.92%	10.68B

Other Biotechnology & Medical Research